26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Clinical presentations of giant cell arteritis (GCA) are protean, and it is vital to make a secure diagnosis and exclude mimics for urgent referrals with suspected GCA. The main objective was to develop a joined-up, end-to-end, fast-track confirmatory/exclusionary, algorithmic process based on a probability score triage to drive subsequent investigations with ultrasound (US) and any appropriate additional tests as required.

          Methods

          The algorithm was initiated by stratifying patients to low-risk category (LRC), intermediate-risk category (IRC) and high-risk category (HRC). Retrospective data was extracted from case records. The Southend pretest probability score (PTPS) overall showed a median score of 9 and a 75th percentile score of 12. We, therefore, classified LRC as PTPS <9, IRC 9–12 and HRC >12. GCA diagnosis was made by a combination of clinical, US, and laboratory findings. The algorithm was assessed in all referrals seen in 2018–2019 to test the diagnostic performance of US overall and in individual categories.

          Results

          Of 354 referrals, 89 had GCA with cases categorised as LRC (151), IRC (137) and HRC (66). 250 had US, whereas 104 did not (score <7, and/or high probability of alternative diagnoses). In HRC, US showed sensitivity 94%, specificity 85%, accuracy 92% and GCA prevalence 80%. In LRC, US showed sensitivity undefined (0/0), specificity 98%, accuracy 98% and GCA prevalence 0%. In IRC, US showed sensitivity 100%, specificity 97%, accuracy 98% and GCA prevalence 26%. In the total population, US showed sensitivity 97%, specificity 97% and accuracy 97%. Prevalence of GCA overall was 25%.

          Conclusions

          The Southend PTPS successfully stratifies fast-track clinic referrals and excludes mimics. The algorithm interprets US in context, clarifies a diagnostic approach and identifies uncertainty, need for re-evaluation and alternative tests. Test performance of US is significantly enhanced with PTPS.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          2018 Update of the EULAR recommendations for the management of large vessel vasculitis

          Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Trial of Tocilizumab in Giant-Cell Arteritis

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice

                Bookmark

                Author and article information

                Journal
                RMD Open
                RMD Open
                rmdopen
                rmdopen
                RMD Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2056-5933
                2020
                29 September 2020
                : 6
                : 3
                : e001297
                Affiliations
                [1 ] departmentRheumatology , Southend University Hospital NHS Foundation Trust , Westcliff-on-Sea, UK
                [2 ] departmentUnit of Immunology, Rheumatology, Allergy and Rare Diseases , San Raffaele Scientific Institute , Milan, Italy
                [3 ] departmentRheumatology , Marques de Valdecilla University Hospital , Santander, Spain
                Author notes
                Correspondence to Bhaskar Dasgupta; bhaskar.dasgupta@ 123456southend.nhs.uk
                Author information
                http://orcid.org/0000-0002-9562-6748
                http://orcid.org/0000-0002-5440-2078
                http://orcid.org/0000-0002-5523-6534
                Article
                rmdopen-2020-001297
                10.1136/rmdopen-2020-001297
                7547539
                32994361
                47312d02-6cf4-42d5-b836-7ff5a3a8ad4e
                © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 30 April 2020
                : 22 July 2020
                : 05 September 2020
                Funding
                Funded by: Royal College of Physicians of Ireland;
                Award ID: Bresnihan-Molloy international educational fellows
                Categories
                Vasculitis
                Original research

                giant cell arteritis,ultrasonography,glucocorticoids

                Comments

                Comment on this article